Crescent Biopharma CBIO
NASDAQ CBIO
$14.32 +0.06 (+0.42%)
At close: Oct 2, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Asset Writedowns and Impairment (2024)

Updated

Crescent Biopharma (CBIO) recorded Asset Writedowns and Impairment of $34,821 in Q4 2024.

Analysis

Crescent Biopharma (CBIO) Asset Writedowns and Impairment (2024) Analysis & Trends

For FY2024, Crescent Biopharma reported Asset Writedowns and Impairment of $400,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Crescent Biopharma 397.47 Mn -309.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 34,821.00
API Access

Crescent Biopharma Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=CBIO&period=max&api_key=YOUR_API_KEY